Table 3. Associations Between Sex and Gender and Elevated CVD Risk Scores Among 221 Transgender Women, 2,983 Cisgender Women, and 13,467 Cisgender Men Alive and Engaged in Continuity HIV Care in the CNICS, 2014–2018 (or contributing cohort-specific administrative censoring date)*.
| Pooled Cohort Equation (PCE) | Framingham Risk Score (FRS) | |||||||
|---|---|---|---|---|---|---|---|---|
| Crude | Adjusted* | Crude | Adjusted* | |||||
| Prevalence Ratio | 95% CI | Prevalence Ratio | 95% CI | Prevalence Ratio | 95% CI | Prevalence Ratio | 95% CI | |
| Transgender Women Classified by Birth Sex† Compared to: | ||||||||
| Cisgender Women | 1.03 | (0.65, 1.63) | 2.52 | (1.08, 5.86) | 1.06 | (0.79, 1.43) | 2.58 | (1.71, 3.89) |
| Cisgender Men | 0.77 | (0.49, 1.21) | 1.25 | (0.54, 2.87) | 0.70 | (0.53, 0.94) | 1.25 | (0.84, 1.86) |
|
Transgender Women Classified According to History of Exogenous Sex Hormone Use†
Compared to: PresentFemalesb by Present Sex (Female) |
||||||||
| Cisgender Women | 0.75 | (0.44, 1.28) | 2.14 | (0.79, 5.81) | 0.77 | (0.54, 1.10) | 1.77 | (0.97, 3.24) |
| Cisgender Men | 0.56 | (0.33, 0.96) | 1.06 | (0.40, 2.85) | 0.51 | (0.36, 0.72) | 0.86 | (0.47, 1.55) |
| Transgender Women Classified by Current Gender* Compared to: | ||||||||
| Cisgender Women | 0.35 | (0.14, 0.84) | 1.52 | (0.38, 6.08) | 0.48 | (0.30, 0.76) | 1.26 | (0.53, 2.96) |
| Cisgender Men | 0.26 | (0.11, 0.62) | 0.75 | (0.19, 2.99) | 0.32 | (0.20, 0.50) | 0.61 | (0.26, 1.42) |
*Adjusted for race, age, most recent viral load (<400 versus ≥400 copies/mL), most recent CD4 cell count, study site, cumulative years of exposure to antiretroviral therapy, and any history of exposure to an abacavir-containing antiretroviral therapy regimen
†In calculations of PCE risk score and FRS